CONQUEST Clinical Platform Study to Combat Scleroderma: A multicenter, double-blind, randomized, placebo-controlled phase 2b clinical platform study to assess the safety and efficacy of investigational products in participants with interstitial lung disease due to systemic sclerosis
Résumé de l'étude
Systemic sclerosis (SSc) is a rare chronic disease that affects the skin and internal organs. The lungs are affected in the majority of patients with SSc. The lung disease associated with SSc is referred to as interstitial lung disease (shortened to SSc-ILD). This study platform allows for the investigation of different investigational products under the same conditions, which can be adjusted over time. Through this study platform, the development of new drugs for SSc-ILD is accelerated, namely (a) by parallel testing of multiple drugs and (b) by reducing the number of study participants needed for significant results. The study design also assigns fewer participants to a placebo, allowing more participants to potentially benefit from the active drug. Some participants may need to interrupt some of their stable standard therapies for SSc-ILD. In the event of an unexpected
(BASEC)
Intervention étudiée
Participants will be randomly assigned to one of the available treatment regimens: currently either Amlitelimab/placebo or BI 1015550/placebo. Amlitelimab is a monoclonal antibody (laboratory-made protein). It is intended to bind to a protein called OX40 ligand, which alters the function of certain cells in the immune system, and inhibit it. The OX40 ligand is believed to play an important role in the scarring process. Individuals who have received Amlitelimab in other studies reported the following side effects: headaches, fatigue, upper respiratory tract infection, flu-like illness, nausea, fever, sore throat, diarrhea, vomiting, excessive sweating (hyperhidrosis), and pain at the injection site. BI 1015550 inhibits the protein PDE4B, which contributes to the coordination of the fibrotic process (scarring) in the lung. BI 1015550 also appears to be beneficial in another (but similar) lung disease.
(BASEC)
Maladie en cours d'investigation
The lung disease associated with systemic sclerosis (SSc), known as interstitial lung disease (shortened to SSc-ILD).
(BASEC)
The study will include men and women aged 18 years and older, who have been diagnosed with SSc within 5 years prior to study enrollment and the presence of SSc-ILD has been confirmed in the 3 months prior to the start of study treatment. (BASEC)
Critères d'exclusion
1. Presence of clinically significant lung abnormalities that are not consistent with ILD (e.g., scarring due to previous active tuberculosis [TB], sarcoidosis, lung mass, or other findings unrelated to SSc-ILD as determined by a local radiologist/researcher) 2. Previous stem cell transplantation, bone marrow transplantation, chimeric antigen receptor T-cell therapy, or organ transplantation 3. Women who are pregnant, breastfeeding, or planning a pregnancy during the clinical study (BASEC)
Lieu de l’étude
Zurich
(BASEC)
Sponsor
Scleroderma Research Foundation Medpace Switzerland AG
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
PD Dr.med. Carmen-Marina Mihai
+41 (0)43 254 14 39
carmen-marina.mihai@clutterusz.chUniversity Hospital Zürich, Department of Rheumatology
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Commission cantonale de Zurich
(BASEC)
Date d'approbation du comité d'éthique
20.12.2024
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
CONQUEST Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants with Interstitial Lung Disease Secondary to Systemic Sclerosis (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible